1-3 of 3
Michael Schmidt
Close
Sort by
Journal Articles

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

Jennifer Watkins-Yoon, Wilson Guzman, Amanda Oliphant, Sara Haserlat, Alan Leung, Claire Chottin, Michael Ophir, Jai Vekeria, Allison P Nelson, Zach Frye, Jason Lajoie, Puru Nanjappa, Sujan Lama, Dalton Markrush, William McConaughy, Xianzhe Wang, Neal Schilling, Doyeob Kim, Paul Wu, Lucy Liu, Kenneth Rogers, Francois Villinger, Bing Gong, Stephen Hamilton, Piotr Bobrowicz, Thomas Schuetz, Michael Schmidt, Monia Draghi
Journal: Blood
Blood (2019) 134 (Supplement_1): 3182.
https://doi.org/10.1182/blood-2019-128749
Published: 2019
Journal Articles

Treatment of Osteopenia/Osteoporosis after Allogeneic Hematological Cell Transplantation with Zoledronic Acid.

Wolfgang Hill, MD, Johanna Ullmann, Andrea Baur, MD, Georg Ledderose, MD, Johanna Tischer, MD, Dieter Muehlbayer, MD, Andreas Hausmann, MD, Michael Schmidt, Ulrike Haus, Hans-Jochem Kolb, MD
Journal: Blood
Blood (2006) 108 (11): 3368.
https://doi.org/10.1182/blood.V108.11.3368.3368
Published: 2006
Journal Articles

A First Mutation in the Human Tissue Factor Pathway Inhibitor Gene Encoding [P151L]TFPI

Knut Kleesiek, Michael Schmidt, Christian Götting, Thomas Brinkmann, Wolfgang Prohaska
Journal: Blood
Blood (1998) 92 (10): 3976–3977.
https://doi.org/10.1182/blood.V92.10.3976
Published: 1998